Hereditary spastic paraplegia arises from pathogenic variants across numerous genes. Among those implicated are AP4M1 on chromosome 7, FICD on chromosome 12, KIF5A on chromosome 12, MARS1 on chromosome 12, NFU1 on chromosome 2, PCYT2 on chromosome 17, PLP1 on the X chromosome, REEP2 on chromosome 5, SPTSSA on chromosome 14, and UCHL1 on chromosome 4, which carries a definitive disease association. These genes are involved in diverse cellular functions, and the inheritance patterns vary by subtype, including autosomal dominant, autosomal recessive, and X-linked forms.

Diagnosis of hereditary spastic paraplegia is established through a combination of clinical evaluation, neurological examination, family history assessment, and molecular genetic testing. The identification of pathogenic variants in associated genes such as UCHL1, PLP1, KIF5A, and others confirms the diagnosis. Neuroimaging and electrophysiological studies may support clinical findings and assist in subtype differentiation.

No universally established clinical practice guidelines exist for hereditary spastic paraplegia as a whole. Management of PLP1-related disorders, for example, is guided by expert consensus in the absence of published formal guidelines. There are currently 8 active clinical trials exploring interventions for hereditary spastic paraplegia, reflecting ongoing efforts to develop targeted therapies.

The prognosis in hereditary spastic paraplegia varies considerably based on the genetic subtype and clinical form. Progressive lower limb spasticity is a consistent feature, and the rate of neurological decline differs widely. Complex forms with additional multisystem involvement generally carry a more guarded long-term outlook.

Research into hereditary spastic paraplegia is active, with 8 ongoing clinical trials currently underway. Genetic discoveries continue to expand the known landscape of causative genes, and studies into the cellular mechanisms of associated proteins such as UCHL1 and KIF5A are informing the development of potential therapeutic strategies.